Business Context and Reporting Period
Company: Village Farms International, Inc. (VFF)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: VFF operates primarily in the cannabis sector through subsidiaries Pure Sunfarms (Canada), Rose LifeScience (Quebec), VFN (Netherlands), and Balanced Health (U.S. CBD). The company also maintains "Other" operations including produce (via a related party agreement with Verdexa) and clean energy. In Q1 2026, the company reorganized into a single reportable segment: Cannabis.
Key Financial Metrics
| Metric (in thousands USD) | 3 Months Ended June 30, 2026 |
6 Months Ended June 30, 2026 |
|---|---|---|
| Total Revenue | $63,977 | $114,215 |
| Gross Profit | $29,973 | $50,959 |
| Gross Margin | 47% | 45% |
| Net Income (Attributable to Shareholders) | $7,145 | $10,062 |
| Adjusted EBITDA (Continuing Ops) | $15,411 | $25,311 |
| Cash and Cash Equivalents | $72,931 | $72,931 |
| Total Debt (Current + Long-term) | $39,962 | $39,962 |
| Working Capital | $109,718 | $109,718 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 7% year-over-year (YoY) for the quarter and 15% YoY for the six months. This was driven primarily by a 74% (quarter) and 104% (six months) surge in International Export sales, particularly to Germany.
- Margin Expansion: Gross margin improved significantly to 47% in Q2 2026 from 37% in Q2 2025. This expansion resulted from higher volumes of lower-cost bulk flower exports and improved yields at Delta facilities.
- Discontinued Operations: Net income comparisons are skewed by the prior year. Q2 2025 included $16.3 million in income from discontinued operations (sale of Texas greenhouses to Verdexa), whereas Q2 2026 had no such income.
- Cost of Sales: Decreased 9% YoY in Q2 due to favorable product mix shifts and operational efficiencies, despite higher overall volume.
- Foreign Exchange: The company recorded a foreign exchange loss of $0.6 million in Q2 2026, compared to a gain of $1.8 million in Q2 2025, impacting pre-tax income.
Guidance, Outlook, and Risks
- Capital Markets Activity: On June 8, 2026, the company completed a registered direct offering of 7.5 million shares at $2.00/share, raising approximately $15 million for working capital. Concurrently, the company repurchased 2.2 million shares for $6.8 million during the six-month period.
- Expansion: The company commenced cultivation at its Phase II facility in Groningen, Netherlands, and accelerated technology upgrades at the Delta 2 greenhouse expansion in Canada, targeting full capacity of 40 metric tonnes by mid-2027.
- Debt Management: The company extended the maturity of its FCC Term Loan to 2031 and reduced the interest margin by 50 basis points. It also drew down an additional $8.3 million on its Pure Sunfarms Term Loan in June 2026.
- Risks:
- Regulatory: Significant uncertainty regarding the legal status of cannabis and CBD in the U.S., including potential impacts from the Continuing Appropriations Act of 2026.
- Market: Declining U.S. Cannabis sales due to unregulated hemp-derived products and state regulatory changes.
- Financial: Exposure to variable interest rates and foreign exchange fluctuations (CAD/USD).
Investor Verification Checklist
- Export Sustainability: Verify the durability of the 74% YoY growth in International Exports and the specific contract terms with German/European distributors.
- U.S. CBD Headwinds: Assess the long-term impact of state-level regulatory changes and unregulated hemp competition on the Balanced Health segment.
- Capital Allocation: Review the balance between the recent $15M equity raise and the ongoing $6.8M share repurchase program to understand management's view on share price and liquidity needs.
- Debt Covenants: Confirm continued compliance with financial covenants under the FCC Term Loan and Pure Sunfarms facilities, particularly given the increased leverage from recent draws.
- Discontinued Operations: Ensure future earnings comparisons exclude the one-time $20M gain from the Verdexa transaction recognized in 2025.